Drug Trial Radar · NCT07055451
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Aug 12, 2025
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 120 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1). The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.
Conditions
- HIV-1-infection
Interventions
B/F/TAFDrug
Tablet for oral suspension administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate BirthTime frame: First dose date up to 8 Weeks
- Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities Through Week 8 After Neonate BirthTime frame: First dose date up to 8 Weeks
- Pharmacokinetic (PK) parameters for Bictegravir (BIC): AUCinfTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: AUClastTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: AUC0-24hTime frame: Predose up to 24 hours postdose
- PK parameters for BIC: CmaxTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: TmaxTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: CminTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: C24hTime frame: At 24 hours postdose
- PK parameters for BIC: t1/2Time frame: Predose up to 72 hours postdose
- PK parameters for BIC: Apparent CL/FTime frame: Predose up to 72 hours postdose
- PK parameters for BIC: Apparent Vz/FTime frame: Predose up to 72 hours postdose
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center (inpatient hospital)
Los Angeles, California
Grady Health System - Ponce de Leon Center
Atlanta, Georgia
St Jude Children's Research Hospital
Memphis, Tennessee
Family Centre for Research with Ubuntu (FAMCRU)
Cape Town, South Africa
Durban International Clinical Research Site, Enhancing Care Foundation
Durban, South Africa
Perinatal HIV Research Unit (PHRU)
Gauteng, South Africa
WITS RHI Shandukani Research Centre
Johannesburg, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.